HOXC6 promotes cervical cancer progression by transcriptionally upregulating BCL2 to enhance anti-apoptotic effects and drive tumor cell proliferation (36) In prostate cancer, HOXC6 promotes tumor cell survival by transcriptionally repressing proapoptotic factors NEP and IGFBP-3, and its knockdown induces caspase-dependent apoptosis in both androgen-dependent and -independent cancer cells (37). Here, BCL2 is linked to neoplasm.